2935 related articles for article (PubMed ID: 23129602)
1. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
2. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
[TBL] [Abstract][Full Text] [Related]
3. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.
Giugliano RP; Desai NR; Kohli P; Rogers WJ; Somaratne R; Huang F; Liu T; Mohanavelu S; Hoffman EB; McDonald ST; Abrahamsen TE; Wasserman SM; Scott R; Sabatine MS;
Lancet; 2012 Dec; 380(9858):2007-17. PubMed ID: 23141813
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study.
Koren MJ; Scott R; Kim JB; Knusel B; Liu T; Lei L; Bolognese M; Wasserman SM
Lancet; 2012 Dec; 380(9858):1995-2006. PubMed ID: 23141812
[TBL] [Abstract][Full Text] [Related]
6. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
Raal FJ; Stein EA; Dufour R; Turner T; Civeira F; Burgess L; Langslet G; Scott R; Olsson AG; Sullivan D; Hovingh GK; Cariou B; Gouni-Berthold I; Somaratne R; Bridges I; Scott R; Wasserman SM; Gaudet D;
Lancet; 2015 Jan; 385(9965):331-40. PubMed ID: 25282519
[TBL] [Abstract][Full Text] [Related]
7. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.
Stein EA; Honarpour N; Wasserman SM; Xu F; Scott R; Raal FJ
Circulation; 2013 Nov; 128(19):2113-20. PubMed ID: 24014831
[TBL] [Abstract][Full Text] [Related]
8. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins.
Dias CS; Shaywitz AJ; Wasserman SM; Smith BP; Gao B; Stolman DS; Crispino CP; Smirnakis KV; Emery MG; Colbert A; Gibbs JP; Retter MW; Cooke BP; Uy ST; Matson M; Stein EA
J Am Coll Cardiol; 2012 Nov; 60(19):1888-98. PubMed ID: 23083772
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA
J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922
[TBL] [Abstract][Full Text] [Related]
10. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
[TBL] [Abstract][Full Text] [Related]
11. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
[TBL] [Abstract][Full Text] [Related]
12. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy.
Cho L; Rocco M; Colquhoun D; Sullivan D; Rosenson RS; Dent R; Xue A; Scott R; Wasserman SM; Stroes E
Clin Cardiol; 2014 Mar; 37(3):131-9. PubMed ID: 24477778
[TBL] [Abstract][Full Text] [Related]
13. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.
Stein EA; Mellis S; Yancopoulos GD; Stahl N; Logan D; Smith WB; Lisbon E; Gutierrez M; Webb C; Wu R; Du Y; Kranz T; Gasparino E; Swergold GD
N Engl J Med; 2012 Mar; 366(12):1108-18. PubMed ID: 22435370
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
Raal FJ; Honarpour N; Blom DJ; Hovingh GK; Xu F; Scott R; Wasserman SM; Stein EA;
Lancet; 2015 Jan; 385(9965):341-50. PubMed ID: 25282520
[TBL] [Abstract][Full Text] [Related]
15. Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy.
Kohli P; Desai NR; Giugliano RP; Kim JB; Somaratne R; Huang F; Knusel B; McDonald S; Abrahamsen T; Wasserman SM; Scott R; Sabatine MS
Clin Cardiol; 2012; 35(7):385-91. PubMed ID: 22714699
[TBL] [Abstract][Full Text] [Related]
16. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
Blom DJ; Hala T; Bolognese M; Lillestol MJ; Toth PD; Burgess L; Ceska R; Roth E; Koren MJ; Ballantyne CM; Monsalvo ML; Tsirtsonis K; Kim JB; Scott R; Wasserman SM; Stein EA;
N Engl J Med; 2014 May; 370(19):1809-19. PubMed ID: 24678979
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
Ginsberg HN; Rader DJ; Raal FJ; Guyton JR; Baccara-Dinet MT; Lorenzato C; Pordy R; Stroes E
Cardiovasc Drugs Ther; 2016 Oct; 30(5):473-483. PubMed ID: 27618825
[TBL] [Abstract][Full Text] [Related]
18. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.
Stroes E; Colquhoun D; Sullivan D; Civeira F; Rosenson RS; Watts GF; Bruckert E; Cho L; Dent R; Knusel B; Xue A; Scott R; Wasserman SM; Rocco M;
J Am Coll Cardiol; 2014 Jun; 63(23):2541-2548. PubMed ID: 24694531
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial.
Koren MJ; Giugliano RP; Raal FJ; Sullivan D; Bolognese M; Langslet G; Civeira F; Somaratne R; Nelson P; Liu T; Scott R; Wasserman SM; Sabatine MS;
Circulation; 2014 Jan; 129(2):234-43. PubMed ID: 24255061
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.
Kereiakes DJ; Robinson JG; Cannon CP; Lorenzato C; Pordy R; Chaudhari U; Colhoun HM
Am Heart J; 2015 Jun; 169(6):906-915.e13. PubMed ID: 26027630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
